Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.

@article{Wang2007OptimizingAP,
  title={Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.},
  author={Jinjuan Wang and Michael C. Jensen and Yukang Lin and Xingwei Sui and Eric Y-T. Chen and Catherine G. Lindgren and Brian G Till and Andrew A. Raubitschek and Stephen J. Forman and Xiaojun Qian and Scott E. James and Philip D. Greenberg and Stanley R Riddell and Oliver W Press},
  journal={Human gene therapy},
  year={2007},
  volume={18 8},
  pages={712-25}
}
We previously demonstrated the feasibility of generating therapeutic numbers of cytotoxic T lymphocyte (CTL) clones expressing a CD20-specific scFvFc:CD3zeta chimeric T cell receptor (cTCR), making them specifically cytotoxic for CD20+ B lymphoma cells. However, the process of generating and expanding he CTL clones was laborious, the CTL clones expressed the cTCR at low surface density, and they exhibited suboptimal proliferation and cytotoxicity. To improve the performance of the CTLs in vitro… CONTINUE READING